Evidence map›Paper›PMID 41358296›Full record

ArticlemedRxiv : the preprint server for health sciences2025

Temporal Trends in Artemisinin Partial Resistance and Other Antimalarial Drug Mutations in

Alfred Simkin, Salehe Mandai, Abebe A Fola, Neeva Wernsman Young, Dativa Pereus, Catherine Bakari, Rashid A Madebe, Misago D Seth, Rule B Mrengela, Angelina J Kisambale and 16 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors.

Alfred SimkinDepartment of Pathology and Laboratory Medicine, Brown University, Providence, RI, USA.
Salehe MandaiIfakara Health Institute, Dar es Salaam, Tanzania.
Abebe A FolaDepartment of Pathology and Laboratory Medicine, Brown University, Providence, RI, USA.
Neeva Wernsman YoungDepartment of Pathology and Laboratory Medicine, Brown University, Providence, RI, USA.
Dativa PereusIfakara Health Institute, Dar es Salaam, Tanzania.
Catherine BakariIfakara Health Institute, Dar es Salaam, Tanzania.
Rashid A MadebeNational Institute for Medical Research, Dar es Salaam, Tanzania.
Misago D SethNational Institute for Medical Research, Dar es Salaam, Tanzania.
Rule B MrengelaIfakara Health Institute, Dar es Salaam, Tanzania.
Angelina J KisambaleIfakara Health Institute, Dar es Salaam, Tanzania.
Gervas A ChachaNational Institute for Medical Research, Dar es Salaam, Tanzania.
Celine I MandaraNational Institute for Medical Research, Dar es Salaam, Tanzania.
Filbert FrancisNational Institute for Medical Research, Dar es Salaam, Tanzania.
Daniel MbwamboNational Malaria Control Programme, Dodoma, Tanzania.
Issa GarimoNational Malaria Control Programme, Dodoma, Tanzania.
Frank ChackyNational Institute for Medical Research, Dar es Salaam, Tanzania.
Sijenunu AaronNational Malaria Control Programme, Dodoma, Tanzania.
Abdallah LusasiNational Malaria Control Programme, Dodoma, Tanzania.
Fabrizio MolteniSwiss Tropical Public Health Institute, Dar es Salaam, Tanzania.
Ritha J A NjauDepartment of Parasitology and Medical Entomology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Stella KajangePresident's Office, Regional Administration and Local Government, Dodoma, Tanzania.
Samwel L NhigaNational Malaria Control Programme, Dodoma, Tanzania.
Ally MohamedPresident's Office, Regional Administration and Local Government, Dodoma, Tanzania.
Jonathan J JulianoDivision of Infectious Diseases, University of North Carolina School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Deus S IshengomaIfakara Health Institute, Dar es Salaam, Tanzania.
Jeffrey A BaileyDepartment of Pathology and Laboratory Medicine, Brown University, Providence, RI, USA.

Funding

Artemisinin Resistance in Africa: its emergence and evolution in RwandaR01AI156267 · NIAID · BROWN UNIVERSITY · PI BAILEY, JEFFREY A., JULIANO, JONATHAN J · 2021 to 2024
$3.0M
Mentoring in Translational Malaria GenomicsK24AI134990 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Jonathan J Juliano · 2018 to 2026
$1.6M
Understanding Emerging artemisinin partner drug resistance in eastern AfricaR01AI189911 · NIAID · UNIVERSITY OF NOTRE DAME · PI JEFFREY A. BAILEY, Michael T Ferdig · 2025 to 2026
$1.4M
Predicting the spread of antimalarial drug resistance using deep learning surrogatesR01AI190302 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Jonathan J Juliano, Robert Verity · 2025 to 2026
$1.3M
NIAID NIH HHS K24 AI134990NIAID NIH HHS R01 AI156267NIAID NIH HHS R01 AI189911NIAID NIH HHS R01 AI190302
6 · The paper itself

Abstract

Artemisinin-based combination therapies (ACTs) remain the cornerstone of malaria treatment, yet the emergence of artemisinin partial resistance (ART-R) in Africa threatens their efficacy. ART-R is primarily associated with mutations in the

Indexed as

artemisiningenomicskelchmalariaPlasmodium falciparumresistancesurveillanceTanzania

Identifiers

PMID41358296
PMCPMC12676548

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.